Her science background helps her predict whether or not drugs will win approval and she's able to judge the riskrewardprofile based upon the current midstage clinical study.
Bottom line: If, consistent with our base-case expectation, the U.S. averts a recession, equities are inexpensive enough to provide investors with an attractive risk-reward profile.